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Assessment of Hepatotoxic Potential
by J. E. Gray*
Philosophic concepts and pragmatic approaches toward improved understanding of the effects
ofdrugs in the hepatocyte are reviewed. No set pattern of studies is advocated but rather observa-
tions are encouraged within the framework of studies that provide for varied exposure of the
hepatocyte. Clinical usage should be imitated to provide earliest possible indications oftoxicity in
man. The need for definitive characterization through utilization of appropriate methodology
derived from cross-fertilization ofrelated disciplines is stressed. Both minimal and maximal dose
effects should be established. Selected use of electron microscopy has become essential for
characterizing responses ofthe liver to injury. The advantages ofthe toluidine blue-stained Epon
"thick" sections are emphasized. Such observations are used to implement the utility of serial
biopsies from the beagle dogprior to and during long-term study of potential hepatic injury. Ex-
amples ofthe critical effects ofdrug concentration within thehepatocyte are presented.
Although we are conditioned to look to the
liver, characterization of the hepatotoxic poten-
tial of a new chemical or drug can be a humbling
experience. Safety studies in animals are more
predictive ofcertain types ofhepatic disease than
of others. Sensitizing agents, for example, rarely
produce alterations in the liver of experimental
animals. Their effects are independent, it seems,
ofthe dose and are therefore often unpredictable.
Furthermore, it has been the experience of many
that it is almost always impossible to evaluate
exactly the factor that makes a substance toxic
to the liver. Only in recent years with the concept
of free-radical formation has some semblance of
common understanding been approached of what
is probably the most widely studied hepatotoxin,
carbon tetrachloride.
It is by intention that I will restrict my discus-
sion chiefly to the safety assessment of drugs;
i.e., chemicals to which man is deliberately expos-
ed for therapeutic purposes. The reason for this
is that my presentation will be based chiefly on
experiences with, perhaps, a helpful smattering
of philosophy. At the onset we recognize that
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most classes of drugs have been associated with
hepatic reactions. Clinical (1) and pathologic (2)
effects ofdrugs in the liver ofman have been com-
piled into long lists. Based on a similarity in
chemical structure, the word to the wise would be
to consider a new drug suspect and proceed ac-
cordingly.
We have passed from the time in which a diag-
nosis of the effects in the liver of a therapeutic
agent was often sufficient to a new era in which
definitive characterizations ofinjury produced by
new drugs are being increasingly made. We can
follow this progress in a tabulation of the papers
that have been published in Toxicology and Ap-
plied Pharmacology (TAP) on liver injury with
morphologic characterization during the past 16
years. As shown in Table 1, 40 such papers were
published during the first 11 years and 55 during
the past 5 years. While part of the increased rate
of publication from 3.6 to 11/yr is due to increas-
ed number of TAP volumes issued annually, it is
perhaps even more pertinent that 14 of the 55
papers in the past 5 years utilized electron
microscopy to define the nature of the injury in
the hepatocyte.
Many types of liver injury are represented in
these 95 papers (Table 2). Fully one-third re-
ported that the primary lesion was necrosis of
the hepatocytes. The majority of these were cen-
June 1976 47Table 1. Papers on liverinjurywith morphologic
characterization."
Years Volumes EM/LIb Year Volumes EM/LIb
1959 1 0/4 1970 16, 17 1/10
1960 2 0/4 1971 18, 19,20 3/10
1961 3 0/6 1972 21, 22,23 2/6
1962 4 0/3 1973 24, 25, 26 3/10
1963 5 0/4 1974 27,28,29, 5/19
1964 6 0/2 30
1965 7 0/3 Last 5years 14/55
1966 8, 9 0/2 Total in 16years 14/95
1967 10, 11 0/5
1968 12,12 0/3
1969 14, 15 0/4
First 11 years 0/40
aIn Toxicology andAppliedPharmacology, 1959-1974.
bElectron microscopy/liver injury characterized.
Table 2. Types of liver injury reported in the literature
(1959-1974).a
No. of
Type reports
Necrosis
Focal 9
Centrilobular 25
Midzonal 2
Peripheral necrosis 6
Submassive 3
-Massive 1
Fatty change 7
Cholestasis 2
Cholangiotoxic 14
Progressive
Cirrhosis 1
Neoplasia 12
Hemosiderosis 2
Kupffer cell deposition 2
Porphyria 3
Enlarged common bile duct 2
Granuloma 1
Degenerative hepatocytes 4
Diffuse cloudy swelling 1
Perinuclear vacuolization 1
Total in 95papers 98
a In Toxicology andAppliedPharmacology, 1959-1974.
trilobular in distribution, the frequency being
three times as great as midzonal and peripheral
necrosis combined. Toxic effects in the bile ducts
and neoplasia were also amongthe more common-
ly encountered categories ofinjury. Undoubtedly
not all of these figures represent a true propor-
tion of the incidence of chemically induced injury
in the liver; rather, the relative incidence is
probably skewed by the personal bias of the
research interests ofthe authors.
The Need forDefinitive Characterization
The principal consideration of my discussion of
the safety evaluation process is that it must ac-
complish a definitive characterization of the
hepatotoxic potential of a new drug. One of the
severest drawbacks of toxicologic evaluations in
the past has been the stereotyping of studies so
that the yield of information was often low. De-
finitive characterization implies that "no stones
are left unturned" in the safety evaluation in
animals. We have learned in the past that stones
left unturned may turn up later, often under less
favorable circumstances. Essentials for assess-
ment of hepatotoxicity are: definitive char-
acterization, appropriate methodology, and com-
bined discipline approach. To this end, meth-
odology which contributes understanding to the
response of the liver cell to the drug exposure is
appropriate. Experience has clearly shown that a
cross-fertilization from the methods of related
disciplines is necessary for definitive char-
acterization. Critical and complementary studies
might include, for example, drug effects on
specific enzymes, cell respiration, and other
biochemical measurements of organelles. Metab-
olites of the drug may be identified in tissue and
bile. The liver concentrations of the drug may be
assayed and compared with the sequential ap-
pearance of ultrastructural change. Obviously all
drug candidates do not require the same battery
of studies. Methods which have been used to
estimate hepatotoxicity such as lethality, sleep-
ing time potentiation and sulfobromophthalein
(BSP) retention become less important as more is
learned about the hepatic response.
In most studies of drug-induced injury in the
liver, the preliminary observations are obtained
with function data and light microscopy. A full
spread of dose regimens and sequential observa-
tions are now utilized to study the pathogenesis
and significance of the hepatic response. Much
importance is attached to the manipulation of the
dose regimen from that which produces a minimal
or threshold effect in the hepatocyte to that
which approaches maximal tolerance of the drug.
The importance of understanding these differ-
ences is that it contributes greatly to the con-
fidence with which human therapy can be initi-
ated. It is necessary to learn, if possible, that a
certain response will occur when certain condi-
tions of exposure are met, and even more im-
portantly from a safety standpoint, it is nec-
essary to learn the conditions of exposure such
that the particular response is very unlikely to
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value in terms of the onset, nature, and outcome
of drug-related effects in the hepatocyte should
such occur under extenuating circumstances
during therapy in man. Frequently the conditions
of clinical usage are imitated to provide the
medical investigator with foreknowledge of the
earliest possible indications of toxicity. The
evaluation of parenterally administered drugs
should follow closely the procedures by which the
drug is given to man. Identical therapeutic for-
mulations should be injected in animals prior to
use in man.
Effective Utilization of Electron Microscopy
Formerly, we were mostly concerned with
labeling with a diagnosis, i.e. a descriptive term,
a change we observed in the liver with a light
microscope. This is still a beginning point, but
diagnosis in drug safety evaluation is nolonger an
end in itself. The main problem with safety obser-
vations limited to diagnosis is that it does not tell
us much about what is going on within the
hepatocyte. With the application of electron
microscopy to drug safety evaluations about 10
years ago, the insight into the dynamic state of
the hepatocyte became much broader. Some ul-
trastructural changes were observed to occur
very rapidly. Transient changes were found that
ordinarily were missed previously when a single
terminal observation was made of the liver by
means of light microscopy. The conditions under
which irreversible changes occurred in the
hepatocytes could also be determined much more
precisely. With certain drugs, such as phenobar-
bital (3), erythromycin, clindamycin (4), and
others, the characteristic hepatocyte response
was shown to be ultrastructural; prior inter-
pretation by light microscopy of the changes pro-
duced by these drugs had been quite limited. The
less specific effects of "wear and tear" on the
hepatocyte, such as is embodied in the concept of
focal cytoplasmic degeneration (5) were also
recognized.
Electron microscopy has been utilized effec-
tively as a lead observation to indicate bio-
chemical and pharmacologic studies that may be
appropriate to a particular safety evaluation.
Without biochemical substantiation of altered
protein synthesis, observations of changes in the
endoplasmic reticulum may be oflimited value. In
long-term studies, low grade sequential effects
of therapy can be monitored through the use of
needle biopsy samples processed for electron
microscopy. Electron microscopy is also useful in
defining the limits of tolerance for a new drug.
Minimal or threshold responses of hepatocytes
produced by various routes of administration and
dose regimens can be compared. The latter find-
ings are quite helpful in developing an overall
safety evaluation. Such changes would probably
be inapparent withlightmicroscopy.
In summary, the advantages of electron
microscopy in study of hepatocyte response to
drug injury are: refinement of the pathologic
description; observation of changes that occur
rapidly; detection of transient changes; deter-
mination of irreversible change; characterization
of drug effects that are chiefly ultrastructural in
nature; appraisal of general metabolic state; as a
lead observation to indicate pertinent
biochemical and pharmacologic studies; for
monitoring of sequential effects in long-term
studies; to define limits oftolerance.
Protocols for electron microscope studies re-
quire more forethought and restraint ordinarily
thanthose forlight microscopy. The return for ef-
fort has the promise of being greater with elec-
tron microscopy, but the samplingproblem usual-
ly does not allow for a large number of observa-
tions at one time. Thorough observations sequen-
tially made in the livers of a few animals should
yield superior information to that obtained from a
large number of animals at one interval during
the course of a study of some duration. Therefore
with electron microscopy the design must be se-
lective. It is usually best conceived prior to im-
plementation of the study. Electron microscopic
observations "hooked on" to other studies often
suffer from lack of sufficient control observa-
tions. Certain factors, such as exposure to other
drugs and lack of environmental control, are very
critical in the interpretation of ultrastructural
change in the hepatocyte. Categorically, electron
microscopy is no better than the design of the
study for which it was done. Electron microscopy
is no longer a prestige method, but rather it is an
essential established method for observing re-
sponses of cells to injury or to lack of injury, as
the case may be.
It might have been anticipated that the greater
magnification obtained with electron microscopy
(EM) would bring about a closer correlation of
morphological change with serum enzyme activ-
ities associated with liver function. The results of
some studies (6,7) have not shown, however, that
slight elevations ofserum transaminase activities
specifically reflect ultrastructural changes. The
June 1976 49data do not suggest that one is necessarily predic-
tive of the other during the early stage of altered
function and morphology in the liver cell. It
seems plausible, at present, that these changes
may be, more or less, independent phenomena
which may or may not occur simultaneously.
EM Fallout: The Semithin Epon Section
A very valuable histologic procedure that came
about following the introduction of electron
microscopy has been the preparation of semithin
or thick Epon sections. These sections, which are
0.5 to 2.0 Mm thick, are cut preliminarily from the
same blocks prepared for electron microscopy
and are routinely stained with toluidine blue.
They are indispensable for orientation of the sec-
tion for electron microscopy and, moreover, fre-
quently enable the investigator to decide wheth-
er or not to proceed with a particular block or
embedment. Thus there is a critical time factor
associated with their utility.
The preservation of detail in the semithin sec-
tion is much better than in the paraffin section.
This is often particularly true with liver sections.
Semithin Epon sections are especially valuable
for the study of the distribution of fatty droplets
and myeloid bodies, as both stain intensely with
toluidine blue. Alternatively, frozen sections
stained with Oil Red 0 can be prepared but these
are often unreliable and poor in quality. Myeloid
bodies are not visualized satisfactorily in conven-
tionally stained paraffin sections.
A further advantage of the semithin Epon sec-
tions is that often they are available more quickly
than the paraffin sections. Some pathology labor-
atories are processing Epon blocks from fixation
to. staining the same working day. They can be
routinely processed in 24 hr. The information
they contain is very useful for the "feedback"
that allows the pathologist to interpret paraffin
sections more accurately as well as to make bet-
ter utilization of electron microscopy at the same
time. Their value lies then, in part, that they can
be read "up" to electron microscopy or read
"down" to conventional light microscopy. Such
morphologic correlations are indispensable for
adequate safety evaluations ofthe liver.
SpeciesSelection for Hepatotoxicity Studies
Much of what has been learned about the
hepatotoxicity of drugs in animals has probably
come from the albino rat. The rat is somewhat
less susceptible to most drugs than the dog. This
has been shown repeatedly by the higher dose
regimens of most drugs tolerated by the rat for
long periods of time. Because a single treatment
group consists of 10 or more animals, studies in
the rat are particularly useful for detection of
weight increase or hypertrophy of the liver (8, 9).
This measure of hepatic response is usually more
sensitive than either increases in serum enzyme
activities or light microscope change.
Conventionally, parallel safety studies are
done in the rat and the dog. In studies of several
months duration with a drug of some therapeutic
promise, i.e., with no overt hepatotoxic property,
the dog generally yields the most reliable in-
formation. Besides having a liver that is more
susceptible to injury, the dog is probably also a
better predictor to tolerance in man. In our ex-
perience, the dog is less likely to yield a false
negative prediction than the rat. Such empiric
understanding seemingly has limited value in this
discussion but nonetheless plays heavily in the
evaluation of hepatotoxicity of a new drug. In the
light of this prejudice, it is interesting to reflect
on similarities in the remarks expressed several
years ago by Beyer (10) in favor of the use of the
clean mongrel dog in safety evaluations because
man and the dog had presumably made similar
metabolic adaptations to their environment for a
substantial period of time. My only reservation
on Beyer's confidence in the dog is that ultra-
structual variations in the hepatocyte of the
mongrel dog would more than likely be a major
shortcoming.
The beagle is used widely in drug safety eval-
uation. The ultrastructure of the hepatocyte in
high quality beagles is quite uniform and free of
many ofthe aberrations commonly found in street
dogs and in beagles with compromised back-
grounds (4,11). To achieve high standards of
ultrastructural control, beagles should be raised
in a rigidly controlled environment. Beagles are
most suitable for long-term studies during which
biopsies of the liver and serum enzyme activities
are obtained periodically for sequential appraisal
of the liver response (Table 3). Customarily, the
livers are biopsied with Silverman needles at
least once, usually twice, prior to treatment so
that an adequate ultrastructural baseline is
available in each dog. Posttreatment biopsies are
usually included in the study protocol of some
dogs to register the reversibility of any changes
that may have appeared during the treatment
period. Vacuolation artifacts in the hepatocyte
such as have been associated with electrocution
Environmental Health Perspectives 50Table 3. Suggested schedule formonitoring ofultrastructural
injury in the liverby biopsy.
Type ofsampling Schedule
Pretest sampling Once or twice for individual
baseline data
Short-term sampling First day oftreatment
30min, 1, 2, 4, 8hr
24, 48, 72hr
1 week, 2 weeks
Long-term sampling 1 month
Monthly, bimonthly, tri-
monthly, semiannually
Crisis sampling Attime ofclinical or func-
tional change
Posttreatment 1 to 2 weeks after treatment
discontinued
(12) have been alleviated by the biopsy sampling
procedure.
We have attempted to use the rhesus monkey
in studies of ultrastructural monitoring by bi-
opsy, similar to those in the dog. The effort has
been much more limited in numbers of animals
but thus far the results have been less satisfac-
tory. The hepatic response ofthe monkey to drug
was quite varied and therefore less predictable.
The liver of the monkey by comparison to the
dog, given the same dose regimen, appeared to be
less susceptible to injury.
Comparative Characteristics of the Hepatocyte
Ultrastructure
Inclusion of some of the apparent ultrastruc-
ture characteristics and responses in the rat and
dog seem appropriate to the discussion. Fat
droplets, for example, are frequently present in
small numbers in scattered hepatocytes in the
rat. They are only occasionally encountered in the
hepatocyte of the beagle. The formation of mye-
loid bodies (13) is the typical morphologic expres-
sion of phospholipidosis in both species. This is a
common response in the liver to many chemicals
collectively termed as amphiphilic (14). Myeloid
bodies in rats treated with clindamycin were
usually multicentric whereas those in the dog
consisted of concentrically layered membranes
about a single core of matrix (4). There was some
indication of a broader response in the rat in that
earlier stages in lysosome development (15) were
subject to the formation of whorled membranes.
The response in the dog was restricted largely to
the secondary lysosome or residual body. In con-
trast, fewer myeloid bodies were found in the rat
hepatocyte at comparable treatment levels with
the dog. The lysosomes of the hepatocyte of the
treated dog tend to become larger and more
varied in shape and density than those in the rat
hepatocyte.
In both species, piecemeal effects on various
organelles can be visualized as the dose regimens
are increased. Changes in the mitochondria are
often indicative of irreversible injury. An in-
crease in autophagic vacuoles is noted, and this
suggests that the turnover time of organelles
may be shortened during a treatment period
when drugs are given at levels higher than the
minimal or "threshold" effect dose. Focal
cytoplasmic degradation may, therefore, be ac-
celerated.
DrugConcentrations and Metabolism
In the assessment of the hepatotoxic potential
of a drug it is paramount to determine whether
the drug is excreted principally through the liver
or by the kidney or some other route. Each
metabolite should be identified to learn whether
it enhances or diminishes the toxic effect of the
drug. A dose-related response in the liver is
usually considered to reflect the concentration of
the drug in the hepatocyte. Piecemeal injury of
the ultrastructural organelles appears to be
related to varied concentrations of the drug, in
part, in the hepatocyte. An increased concentra-
tion of a drug may bring about degeneration of an
organelle that had been able to accomodate to
lower levels of the drug. Conversely, the hepat-
ocyte may show improved tolerance, i.e., less
evidence of response, after a few days of treat-
ment and may continue to do so for a limited
period of time or for the duration of long term
study. The latter type of accomodation was
recently reviewed (16). Transient ultrastructural
changes lie within the scope of this type of adap-
tation.
There is increasing evidence that the hepat-
ocyte can handle concentrations of certain drugs
to a rather specific level without functional or
morphological insult. Once the level of minimal or
threshold effect is exceeded, a variety of hepatic
responses may occur depending on nature of the
specific insult. In ultrastructural studies (4) with
clindamycin, for example, myeloid bodies were
seldom observed in a group ofdogs treated orally
with 300 mg/kg for one year. In other dogs
treated with a near maximal tolerated dose of600
mg/kg they formed rapidly, in 30 min or less, and
June 1976 51became abundant in most hepatocytes. The criti-
cal effect of concentration on the hepatic
response is also illustrated by a comparison of
tetracycline levels in the blood serum and liver
(Table 4). The disproportionately greater concen-
Table 5. Mean concentrations of tetracycline in blood serum
and liver ofgroups of three Sprague-Dawley female rats after
intraperitoneal treatment with 100and 300mg/kg.
Time Tetracycline concentration
after IP dose=100 mg/kg IP dose=300 mg/kg
single IP Blood Lie, Blood Lvr
injection, serumg Liver' Bloo Liver,
hr segrm, IAg/g segrm, JAg/g
1 <0.7 <1.1 38.0 342.1
3 36.2 166.7 68.9 832.5
6 25.7 124.8 72.9 804.4
24 1.3 4.6 27.3 183.8
48 <0.7 <1.1 23.3 163.2
tration in the liver offemale rats treated with 300
mg/kg compared with that of rats treated with
100 mg/kg is indicated at 1 hr after injection
(342:1), at 3 hr (833:167), and at 48 hr (163:1).
These concentrations produced distinguishable
accumulations of fat droplets in the hepatocyte
(17). In vitro studies revealed that a precipitate
formed rather abruptly with serum lipoproteins
in the presence of Ca2+ when the concentration of
tetracycline exceeded 200 jg/ml (Fig. 1). This in-
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FIGURE 1. Influence of tetracycline concentration on the for-
mation ofaprecipitate withlipoprotein in rat serumin vitro.
formation, coupled with the bioassay results
which indicated that the concentration of tetra-
cycline in the liver ofrats treated with 300 mg/kg
considerably exceeded 200 pg/g of tissue, offered
a credible basis for the formation of fat droplets
in the space ofDisse (Fig. 2).
Another curious finding may follow the excre-
tion of high levels of a drug by the liver (7).
Under certain circumstances, especially during
an anorexic state, the drug or its metabolites may
accumulate in the bile in the gall bladder in
higher concentration than it was excreted by the
liver. The higher concentration may exceed the
tolerance ofthe gall bladder and may bring about
necrosis of the lining. This could occur without
appreciable change in the hepatocyte observable
by light microscopy.
Implementation of Hepatotoxicity Studies
How, then, do we go about evaluating
hepatotoxic potential of drugs in animals?
Underlying this discussion has been the assump-
tion that no set pattern of observations would be
adequate. All observations are made in the
framework of studies that allow for varied ex-
posure of the hepatocyte to the drug. Allowance
should be made for the accommodation of special
observations as the characterization proceeds.
Some chemicals will require long-term studies if
proliferative responses of the hepatocytes of bile
duct epithelium have occurred or are suspected.
With others, the study time could plausibly be
shortened to a few months in duration. These dif-
ferences are dependent chiefly upon the type of
hepatic response.
Perhaps fewer drug candidates will be studied
in the foreseeable future, but these will be work-
ed on in greater depth than ever before. More
will be learned about each drug before human ex-
posure. This has been made possible by tech-
nological improvements and opportunities for
combined discipline approach. All observations
must be integrated and interpreted in so far as
possible. A continuing challenge exists in altering
the dose regimens and conditions of exposure so
as to minimize the possibility of hepatic injury.
Hepatic injury may be studied during simul-
taneous administration of two or more drugs. No
widespread use of this is foreseen, however,
rather, such studies may be done in selected
situations in which one drug has an effect on the
metabolism of another. The forecast for
assessment of hepatotoxic potential shows
promise for continued optimism. It is sobered by
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FIGURE 2. Epon-embedded section of the liver of a rat treated for 1 day with 300 mg/kg oftetracycline hydrochloride. Numerous
small fat droplets have accumulated about the sinusoids in the spaces of Disse. Some of the periportal cells also show swollen
mitochondria. Toluidine blue-safranin stain. x635.
53 June 1976the foregone understanding that hepatic reac-
tions will continue to occur occasionally during
therapy with many useful and necessary drugs.
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